R S Walters

2.8k total citations · 1 hit paper
25 papers, 2.3k citations indexed

About

R S Walters is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, R S Walters has authored 25 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 12 papers in Oncology and 6 papers in Genetics. Recurrent topics in R S Walters's work include Cancer Treatment and Pharmacology (9 papers), Acute Myeloid Leukemia Research (8 papers) and Acute Lymphoblastic Leukemia research (6 papers). R S Walters is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Acute Myeloid Leukemia Research (8 papers) and Acute Lymphoblastic Leukemia research (6 papers). R S Walters collaborates with scholars based in United States, United Kingdom and Sweden. R S Walters's co-authors include Frankie A. Holmes, Michael J. Keating, G. N. Hortobágyi, Terry L. Smith, R. Theriault, Hagop M. Kantarjian, Emil J. Freireich, D. Frye, A. U. Buzdar and Martin N. Raber and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Blood.

In The Last Decade

R S Walters

25 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

1991 615 citations Frankie A. Holmes, R S Walters et al. JNCI Journal of the National Cancer Institute profile →

Peers

Countries citing papers authored by R S Walters

Since Specialization

Citations

This map shows the geographic impact of R S Walters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R S Walters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R S Walters more than expected).

Fields of papers citing papers by R S Walters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R S Walters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R S Walters. The network helps show where R S Walters may publish in the future.

Co-authorship network of co-authors of R S Walters

This figure shows the co-authorship network connecting the top 25 collaborators of R S Walters. A scholar is included among the top collaborators of R S Walters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R S Walters. R S Walters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase III study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with metastatic breast cancer: Final results 2006 ·Journal of Clinical Oncology ·(unknown), Jaime Mejia, Banu Arun, R. Adinin, R S Walters, Abenaa M. Brewster, Kristine Broglio, Guosheng Yin, Francisco J. Esteva, Gabriel N. Hortobágyi, Vicente Valero	5
2	Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results 1999 ·Annals of Oncology ·Frankie A. Holmes, Vicente Valero, R S Walters, R. Theriault, Daniel J. Booser, Harry Gibbs, Giuseppe Fraschini, A. U. Buzdar, Jie Willey, D. Frye, Lina Asmar, G. N. Hortobágyi	14
3	Daily Oral Etoposide in Patients With Heavily Pretreated Metastatic Breast Cancer 1998 ·American Journal of Clinical Oncology ·Lajos Pusztai, R S Walters, Vicente Valero, Richard L. Theriault, Gabriel N. Hortobágyi	18
4	Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. 1996 ·Journal of Clinical Oncology ·Frankie A. Holmes, Timothy Madden, Robert A. Newman, Vicente Valero, R. Theriault, Giuseppe Fraschini, R S Walters, (unknown), Aman U. Buzdar, Jie Willey, G. N. Hortobágyi	142
5	Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. 1995 ·Journal of Clinical Oncology ·Vicente Valero, Frankie A. Holmes, R S Walters, Richard L. Theriault, Leticia Esparza, Giuseppe Fraschini, Gustavo Fonseca, Robert E. Bellet, Aman U. Buzdar, Gabriel N. Hortobágyi	325
6	Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. 1991 ·Journal of Clinical Oncology ·Giuseppe Fraschini, A. A. Ciociola, Leticia Esparza, D. C. Templeton, (unknown), R S Walters, G. N. Hortobágyi	34
7	Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer breakdown → 1991 ·JNCI Journal of the National Cancer Institute ·Frankie A. Holmes, R S Walters, R. Theriault, A. U. Buzdar, D. Frye, G. N. Hortobágyi, (unknown), (unknown), Martin N. Raber	615
8	Pirarubicin in Combination Chemotherapy for Metastatic Breast Cancer 1990 ·American Journal of Clinical Oncology ·Gabriel N. Hortobágyi, Richard L. Theriault, D. Frye, R S Walters, Giuseppe Fraschini, Charles K. Tashima, J. Ro, (unknown), A. Buzdar	4
9	Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. 1990 ·Journal of Clinical Oncology ·Hagop M. Kantarjian, R S Walters, Michael J. Keating, Terry L. Smith, Stephen O’Brien, Elihu H. Estey, Yang O. Huh, Jorge A. Spinolo, K. A. Dicke, Barthel Barlogie	136
10	Response to salvage therapy and survival after relapse in acute myelogenous leukemia. 1989 ·Journal of Clinical Oncology ·Michael J. Keating, Hagop M. Kantarjian, Terry L. Smith, Elihu H. Estey, R S Walters, Börje S. Andersson, Miloslav Beran, K. B. McCredie, Emil J. Freireich	148
11	STATISTICAL ESTIMATION OF ROLLOVER RISK 1989 ·(unknown), (unknown), (unknown), R S Walters	11
12	Myeloid surface antigen-positive acute lymphoblastic leukemia (My+ ALL): immunophenotypic, ultrastructural, cytogenetic, and molecular characteristics. 1989 ·PubMed ·Craig C. Childs, C Hirsch-Ginsberg, R S Walters, B Andersson, (unknown), J. M. Trujillo, Ann Cork, Sanford A. Stass, Emil J. Freireich, T. F. Zipf	54
13	The characteristics and outcome of patients with late relapse acute myelogenous leukemia. 1988 ·Journal of Clinical Oncology ·Hagop M. Kantarjian, M Keating, R S Walters, K. B. McCredie, E. J. Freireich	66
14	Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. 1988 ·PubMed ·Michael J. Keating, Terry L. Smith, H. Kantarjian, Ann Cork, R S Walters, José M. Trujillo, K. B. McCredie, E. A. Gehan, Emil J. Freireich	169
15	Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor 1988 ·Blood ·Saroj Vadhan‐Raj, (unknown), A LeMaistre, Michael Keating, R S Walters, (unknown), Walter N. Hittelman, HE Broxmeyer, Gutterman Ju	6
16	A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. 1987 ·Journal of Clinical Oncology ·Michael J. Keating, E. A. Gehan, Terry L. Smith, Elihu H. Estey, R S Walters, Hagop M. Kantarjian, K. B. McCredie, Emil J. Freireich	34
17	Therapy of chronic myelogenous leukemia with recombinant interferon- gamma 1987 ·Blood ·Razelle Kurzrock, Moshe Talpaz, H Kantarjian, R S Walters, S. Saks, JM Trujillo, Gutterman Ju	1
18	Therapy of chronic myelogenous leukemia with recombinant interferon- gamma 1987 ·Blood ·Razelle Kurzrock, Moshe Talpaz, H Kantarjian, R S Walters, S. Saks, JM Trujillo, Gutterman Ju	75
19	Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. 1986 ·Journal of Clinical Oncology ·Hagop M. Kantarjian, Michael J. Keating, R S Walters, Terry L. Smith, (unknown), K. B. McCredie, Emil J. Freireich	217
20	Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. 1984 ·Journal of Clinical Oncology ·Elihu H. Estey, M Keating, Terry L. Smith, K. B. McCredie, S S Legha, R S Walters, G. P. Bodey, E. J. Freireich	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact